文献速递肝肾功能剂量调整抗栓抗凝管理药物不良反应与药物警戒

直接口服抗凝药试验中肾功能谱系的血栓栓塞与出血结局

Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.
PubMed 文献 · Clin Pharmacol Ther · 2021-01-19

本研究基于RE-LY(n=18,049)、ARISTOTLE(n=18,187)和ENGAGE AF(n=20,798)三项随机试验,按基线GFR≥60、45-59、<45 mL/min/1.73 m2分层,比较DOAC与华法林使用者卒中/系统性栓塞、出血及复合终点的发生率。结果显示肾功能显著影响口服抗凝药的安全性与有效性,调整后华法林、达比加群和艾多沙班在GFR<60时出血风险升高,而阿哌沙班未见出血风险增加。

要点

  • 肾功能下降与华法林、达比加群、艾多沙班出血风险升高相关
  • 阿哌沙班在GFR 45-59及<45时未见出血风险增加
  • 肾功能显著影响口服抗凝药的安全性与有效性

核心结论

  • 肾功能显著影响口服抗凝药的安全性与有效性。
  • 调整后华法林、达比加群和艾多沙班在GFR<60时出血风险升高,阿哌沙班未见增加。

研究设计与样本

  • 基于RE-LY(n=18,049)、ARISTOTLE(n=18,187)和ENGAGE AF(n=20,798)三项随机试验的分析。
  • 基线肾功能按GFR≥60(参照)、45-59、<45 mL/min/1.73 m2分层,比较各层事件发生率。
  • 采用Cox回归、意向性治疗分析并调整已知预测因素估计风险比。

主要发现

  • 25-29%参与者GFR 45-59,9.5-12.6%参与者GFR<45。
  • 华法林使用者在GFR 45-59和<45时出血发生率高于GFR≥60(P<0.0001),ARISTOTLE和ENGAGE中卒中/SEE发生率亦更高(P≤0.05)。
  • 达比加群使用者在GFR 45-59和<45时卒中/SEE(P≤0.02)、出血(P<0.001)及两项复合终点(P<0.0001)发生率更高。
  • 阿哌沙班和艾多沙班使用者在GFR 45-59和<45时出血(P≤0.05)及复合终点(P≤0.05)发生率更高。

关键数值与推荐

  • 调整后华法林使用者在ARISTOTLE和RE-LY中GFR<60时出血风险升高(P<0.05)。
  • 调整后达比加群使用者出血风险升高(P<0.001),艾多沙班使用者出血风险升高(P≤0.005)。
  • 调整后阿哌沙班使用者出血风险未增加(GFR 45-59 P=0.08;GFR<45 P=0.71)。

临床怎么用

  • 临床选用DOAC时应结合基线肾功能评估出血与血栓栓塞风险。
  • 肾功能下降患者使用华法林、达比加群或艾多沙班时需加强出血监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease is a common comorbidity among patients taking direct-acting oral anticoagulants (DOACs). Herein, we evaluate the influence of kidney function on stroke or systemic embolism (SEE), hemorrhage, and composite end points (stroke/SEE/hemorrhage/death and stroke/SEE/death) among patients on DOACs and warfarin. Baseline kidney function was categorized as glomerular filtration rate (GFR) ≥ 60 (reference), 45-59, and < 45mL/min/1.73 m2 for participants in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) (n = 18,049), Apixaban for Reduction in Stroke and Other Thromboembolic Events (ARISTOTLE) (n = 18,187), and The Effective Anticoagulation with Factor Xa Next Generation in AF (ENGAGE AF) (n = 20,798) trials. Incidence of events was compared across GFR categories. Hazard ratios for events were estimated using Cox regression using intention-to-treat analysis adjusting for known predictors. A large proportion of participants had GFR < 60 (25-29% had 45 ≤ GFR < 60 and 9.5-12.6% with GFR < 45). Compared with patients with GFR ≥ 60, warfarin users across the trials with GFR ≥ 45-59 and GFR < 45 had a higher incidence of hemorrhage (P values < 0.0001) and warfarin users in the ARISTOTLE and ENGAGE trials had higher incidence of stroke/SEE (P values ≤ 0.05). Compared with patients with GFR ≥ 60, dabigatran users with GFR ≥ 45-59 and GFR < 45 had a higher incidence of stroke/SEE (P ≤ 0.02), hemorrhage (P < 0.001), and both composite end points (P < 0.0001). Compared with patients with GFR ≥ 60, apixaban and edoxaban users with GFR ≥ 45-59 and GFR < 45 had a higher incidence of hemorrhage (P values ≤ 0.05) and composite end points (P values ≤ 0.05). After adjustment, compared with patients with GFR ≥ 60, warfarin users with GFR < 60 in the ARISTOTLE and RE-LY trials had a higher risk of hemorrhage (P < 0.05), as did dabigatran (P < 0.001) and edoxaban (P ≤ 0.005) users, while apixaban users did not exhibit an increased risk (P = 0.08 GFR ≥ 45-59; P = 0.71 GFR < 45). Kidney function significantly influences the safety and efficacy of oral anticoagulants.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Limdi NA, Beasley TM, Sun J, et al. Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function. Clin Pharmacol Ther. 2021. PMID: 33278832. doi:10.1002/cpt.2131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。